Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
Withdrawn
This medicine's authorisation has been withdrawn
tenecteplase
MedicineHumanWithdrawn
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG has been withdrawn at the request of the marketing authorisation holder.
Product information
09/08/2005
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
- Active substance
- tenecteplase
- International non-proprietary name (INN) or common name
- tenecteplase
- Therapeutic area (MeSH)
- Myocardial Infarction
- Anatomical therapeutic chemical (ATC) code
- B01AD
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.
This page was last updated on